AUSTRALIA
info@sudapharma.com
Facebook
Twitter
Linkedin
YouTube
+61 8 6142 5555
Menu
About Us
Snapshot
Our People
Leadership Team
Management Team
Scientific Advisory Board Members
Corporate Governance and Charters
Technology
Products
Zolpimist™ – Treatment for Insomnia
R&D
Anagrelide: Treatment for Cancer
Sumatriptan: Treatment for Migraine
Cannabinoids (CBD)
Ondansetron : Nausea
Sildenafil : Erectile Dysfunction/PAH
Midazolam: Treatment for Epilepsy & Anxiety
Investors
ASX Announcements
Presentations
Analyst Reports
Media
Contact Us
Annual Reports
30 June 2018
30 June 2017
30 June 2016
Recent Agreements
Latest SUDA Investor Presentation>>
ASX Announcements
26 Nov 20
AGM FY20 Presentation
24 Nov 20
R & D Tax Incentive refund received
17 Nov 20
Investor Presentation November 2020
11 Nov 20
Change of Director’s Interest Notice – P. Hopper
09 Nov 20
Change of Director’s Interest Notice – D.Simmonds
